|
|
|
GTC, USA
2013/4/29
With more than 400 drug candidates for diabetes in active development and in light of the recent US Food and Drug Administration (FDA) guidance to assess cardiovascular risk in clinical trials, the burden to develop novel drugs is greater and the barrier for success has become higher than ever. What will be the next block-buster drug target for T1DM and T2DM? How does the recent FDA guidance affect our approach to develop new medications for diabetes? How do different size companies adapt the best strategy to be competitive in this field? GTC’s 3rd Diabetes Partnering and Deal Making Conference, part of the 3rd Diabetes Summit, is a partnering and business development conference that gives companies an opportunity to network with high-level executives and explore potential collaborations, learn about relevant issues and deals that will affect the industry. This important meeting will be held on April 29-30, 2013 in Boston, MA. The conference will bring together the leading experts on diabetes from both industry and academia to discuss business strategies and opportunities under the current regulatory landscape. We look forward to seeing you at the conference! | | | | Conference Date: April 29-30, 2013
|
|
|
|
|
|
Organized by:
|
|
GTC |
|
Invited Speakers:
|
|
KEYNOTE SPEAKER | | Riccardo Perfetti Vice President, Global Medical Affairs Sanofi | FEATURED SPEAKER | | | | Allan Ertmann Karlsen Corporate Vice President Diabetes Biology & Hagedorn Research Institute Diabetes Research Unit Novo Nordisk A/S | G. Steven Burrill CEO Burrill & Company | Ed Damiano Associate Professor Biomedical Engineering Boston University |
|
| DISTINGUISHED SPEAKERS AND PANELISTS | | Mostafa Analoui Head; Healthcare and Life Sciences The Livingston Group
Barbara Corkey Vice Chair for Research Boston University School of Medicine
John Mc Elroy President and CSO Jenrin Discovery
Kurt Graves Executive Chairman & CEO Intarcia Therapeutics
Bart Henderson President & Founder Rhythm
George Kunos Scientific Director NIAAA/NIH
Tomas Landh Director, Stragegy and Sourcing, Diabetes Research Unit Novo-Nordisk
Randall Nelson Research Professor, Molecular Biomarkers Lab Arizona State University
Karen Segal Senior Vice President Diabetes and Metabolic Diseases Meso Blast
Lauren Shearman Strategic Licensing & Acquisitions Lead Diabetes & Endocrinology External Scientific Affairs Worldwide Licensing & Acquisitions Merck
Peter Stein Head; Development Metabolism Janssen R&D US
Solomon Steiner Managing Director Steiner Ventures
Jim Wang VP, Cardiovascular and Metabolic Diseases Research Crown Bioscience (Taicang) Inc.
Advisory Board Members Helping to Organize the Event
Paul Burton Vice President, Franchise Medical Leader Johnson and Johnson Pharmaceutical Research Division
Richard Caroddo Business Development Executive Medpace
Steven Cohen Senior Director Daiichi Sankyo
Lisa Jansa Chief Executive Officer Exsulin Corporation
Allan Ertmann Karlsen Vice President Novo-Nordisk
Urban Kiernan Senior Scientist Thermo Fischer
Christopher Kiritsy President and Chief Executive Officer, Co-Founder Arisaph Pharmaceuticals
Tomas Landh Director, Strategy and Sourcing, Diabetes Research Unit Novo Nordisk
James Lenhard Research Fellow Johnson & Johnson
Yin Liang Head of In Vivo Section Johnson & Johnson
Jeffrey Pfefferkorn Senior Principal Scientist Pfizer
David Warnock Professor School of Medicine at the University of Alabama at Birmingham
Jim Wang VP, Cardiovascular and Metabolic Diseases Research Crown Bioscience (Taicang) |
|
|
|
|
|
|
Deadline for Abstracts:
|
|
2013/4/20
|
|
|
|
|
|
Registration:
|
|
https://www.gtcbio.com/index.php?option=com_register&cn=3rd%20Diabetes%20Partnering%20and%20Deal%20Making&cid=117
|
|
E-mail:
|
|
Scott.Mccue@gtcbio.com
|
|
|
|
|
|
|
|